Fibroblast growth factor receptor 3 (FGFR3) binding proteins
Z Weng, WM Winston Jr, L Breault, K Meetze… - US Patent …, 2012 - Google Patents
2003/021110.6 A1 11/2003 Tornetta et al. 2004.0005643 A1 1/2004 De Santis et al.
2004.0034. 888 A1 2/2004 Liu et al. 2004/0038339 A1 2/2004 Kufer et al. 2004.0043930 A1 …
2004.0034. 888 A1 2/2004 Liu et al. 2004/0038339 A1 2/2004 Kufer et al. 2004.0043930 A1 …
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
A Gurney, J Lewicki, S Satyal, T Hoey - US Patent 7,723,477, 2010 - Google Patents
6,433,155 B1* 8/2002 Umansky et a1............ 536/235 Cer and specl? cally Iargenng Cancer
Stem cells-The pres? nt 6,660,843 B1* 12/2003 Feige et a1............... 530/3917 invention …
Stem cells-The pres? nt 6,660,843 B1* 12/2003 Feige et a1............... 530/3917 invention …
Frizzled-binding agents and uses thereof
AL Gurney, AK Sato, FT Axelrod, TC Hoey… - US Patent …, 2011 - Google Patents
Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled
receptors are provided. Novel epitopes within the human frizzled receptors which are …
receptors are provided. Novel epitopes within the human frizzled receptors which are …
Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
W Mao, JR Junutula, P Polakis - US Patent 8,937,161, 2015 - Google Patents
6, 2443. A 9, 2000 SR tion of the cysteine engineered anti-TENB2 antibodies are 6,214,345
B1 4/2001 FireStone provided. Cysteine engineered anti-TENB2 antibodies (Ab) 6,248,564 …
B1 4/2001 FireStone provided. Cysteine engineered anti-TENB2 antibodies (Ab) 6,248,564 …
Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
AL Gurney, AK Sato, FT Axelrod, TC Hoey… - US Patent …, 2013 - Google Patents
2011-09-09 Assigned to ONCOMED PHARMACEUTICALS, INC. reassignment ONCOMED
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
JI Rotter, M Dubinsky, SR Targan… - US Patent 11,236,393, 2022 - Google Patents
The present invention relates to methods of prognosing responsiveness to anti-TNFa
therapy by determining the presence or absence of risk factors in the individual. In one …
therapy by determining the presence or absence of risk factors in the individual. In one …
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
J Kan, S Thomson, GM Argast, ME O'connor… - US Patent …, 2018 - Google Patents
2012-06-13 Assigned to OSI Pharmaceuticals, LLC reassignment OSI Pharmaceuticals, LLC
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
Compositions and methods for diagnosing and treating cancer
A Gurney, J Lewicki, S Satyal, T Hoey - US Patent 9,850,311, 2017 - Google Patents
6, 159, 750 A 6, 180, 370 B1 6, 190, 876 B1 6, 197, 523 B1 6, 198, 107 B1 6, 207, 147 B1 6,
218, 166 B1 6, 252, 050 B1 6, 262, 025 B1 6, 353, 150 B1 6, 379, 925 B1 6, 380, 362 B1 6 …
218, 166 B1 6, 252, 050 B1 6, 262, 025 B1 6, 353, 150 B1 6, 379, 925 B1 6, 380, 362 B1 6 …
Frizzled-binding agents and uses thereof
AL Gurney - US Patent 9,499,630, 2016 - Google Patents
RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O ([C@@ H] 1 [C@@] 2
(C [C@@ H](C (C)= C (C2 (C) C)[C@ H](C ([C@] 2 (C)[C@@ H](O) C [C@ H] 3OC [C@] 3 …
(C [C@@ H](C (C)= C (C2 (C) C)[C@ H](C ([C@] 2 (C)[C@@ H](O) C [C@ H] 3OC [C@] 3 …
Methods for detecting gene dysregulation by intragenic differential expression
HR Sanders, M Albitar, A Meloni-Ehrig - US Patent 9,546,404, 2017 - Google Patents
Related US Application Data (63) Continuation of application No. 14/454,124, filed on Aug.
7, 2014, now Pat. No. 9,187,788, which is a continuation of application No. 13/848,974, filed …
7, 2014, now Pat. No. 9,187,788, which is a continuation of application No. 13/848,974, filed …